LYRA

Lyra Therapeutics (LYRA)

Lyra Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:LYRA

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/21	22 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/05/21	22 : 14	GlobeNewswire Inc.	Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/05/06	20 : 59	GlobeNewswire Inc.	Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/05/01	05 : 04	GlobeNewswire Inc.	Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/04/27	05 : 51	GlobeNewswire Inc.	Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/03/22	05 : 01	GlobeNewswire Inc.	Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/03/02	06 : 01	GlobeNewswire Inc.	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/02/15	23 : 18	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/02/15	10 : 35	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/02/15	08 : 18	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/02/15	06 : 51	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/02/15	06 : 18	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/02/14	06 : 34	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/02/02	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/02/02	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LYRA	Lyra Therapeutics Inc
2024/01/08	20 : 13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/12/28	20 : 40	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/12/19	06 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/11/17	07 : 00	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/11/14	07 : 29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/11/08	06 : 23	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/11/08	06 : 09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/11/08	06 : 01	GlobeNewswire Inc.	Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/11/07	21 : 00	GlobeNewswire Inc.	Lyra Therapeutics to Participate in Upcoming Investor Conferences	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/10/16	20 : 00	GlobeNewswire Inc.	Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/09/13	05 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/09/12	20 : 00	GlobeNewswire Inc.	Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/09/06	21 : 00	GlobeNewswire Inc.	Lyra Therapeutics to Participate in Upcoming Investor Conferences	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/09/02	05 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LYRA	Lyra Therapeutics Inc
2023/09/02	05 : 01	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:LYRA	Lyra Therapeutics Inc